KIT S628N

CI-VAR-00004085Explore in graph →CIViC 1659

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
KIT S628N	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID7462 WT and S628N KIT were expressed in COS-7 cells. Both cell types were treated with or without Stem Cell Factor (SCF), which induces KIT autophosphorylation (activation). In western blots, WT KIT was ph… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
KIT S628N	Dasatinib + ImatinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID4791 In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-s… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
KIT S628N	Imatinib	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7463 A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S62… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic